fda.gov vs TrimRx
Market traction comparison · Updated Jul 2026
| fda.gov | TrimRx | Leads | |
|---|---|---|---|
| Monthly Visits | 8.5M | 3.6M | fda.gov |
| Bounce Rate | 59.1% | 57.9% | TrimRx |
| Domain Rating | — | 60 | |
| Est. MRR | — | $249.2K | |
| SEO & Keywords | 30 | 35 | TrimRx |
| Domain Age | 26y 1m | 7y 1m | fda.gov |
fda.gov leads in 2 of 4 dimensions, while TrimRx leads in 2.
Growth Momentum
| fda.gov | TrimRx | Leads | |
|---|---|---|---|
| Monthly Visits | 8.5M | 3.6M | fda.gov |
| MoM Change | +25% | -16% | fda.gov |
| Avg. Session | 2m15s | 2m13s | fda.gov |
| Pages / Visit | 2.5 | 5.1 | TrimRx |
Growth Momentum · Insight
TrimRx is losing traffic (-16%) despite 3.6M monthly visits. fda.gov's +25% growth puts it on a trajectory to overtake.
Acquisition Strategy
| fda.gov | TrimRx | Leads | |
|---|---|---|---|
| Primary Channel | Search 52% | Direct 35% | |
| Bounce Rate | 59.1% | 57.9% | TrimRx |
| SEO & Keywords | 30 | 35 | TrimRx |
Keyword Overlap Rate: 10%
Acquisition Strategy · Insight
fda.gov acquires users primarily through Search (52%), while TrimRx relies on Direct (35%). This reflects fundamentally different go-to-market strategies — fda.gov's higher direct traffic suggests stronger brand recognition or product-led growth, while fda.gov's search reliance means growth is more scalable but more vulnerable to algorithm changes.
Business Maturity
Revenue estimates are derived from public data sources. Actual figures may differ.
| fda.gov | TrimRx | Leads | |
|---|---|---|---|
| Est. MRR | — | $249.2K | |
| Revenue / Visit | — | $0.069 | |
| Domain Age | 26y 1m | 7y 1m | fda.gov |
| Registered | Jul 2000 | Jul 2019 | |
| Expires | Aug 2026 | Jul 2034 |
Business Maturity · Insight
TrimRx has reached $249.2K MRR in 7 years while fda.gov shows no public revenue data after 26 years — suggesting different monetization maturity or disclosure strategies.
Market Position
| fda.gov | TrimRx | Leads | |
|---|---|---|---|
| Domain Rating | — | 60 | |
| Global Rank | #7.9K | #12.9K | fda.gov |
| Category Rank | #4 | #7 | fda.gov |
fda.gov only
TrimRx only
Market Position · Insight
Each has untapped markets the other serves: fda.gov could expand into Brazil, United Kingdom, Canada, while TrimRx could target China, South Korea, Japan.
Key Takeaways
- •TrimRx is losing traffic (-16%) despite 3.6M monthly visits. fda.gov's +25% growth puts it on a trajectory to overtake.
- •fda.gov acquires users primarily through Search (52%), while TrimRx relies on Direct (35%). This reflects fundamentally different go-to-market strategies — fda.gov's higher direct traffic suggests stronger brand recognition or product-led growth, while fda.gov's search reliance means growth is more scalable but more vulnerable to algorithm changes.
- •fda.gov receives 2.3x more monthly traffic than TrimRx (8.5M vs 3.6M).
- •fda.gov is growing (+25%) while TrimRx is declining (-16%).
- •fda.gov acquires traffic primarily through Search (52%), while TrimRx relies on Direct (35%) — fundamentally different acquisition strategies.
- •They share 6 keywords (10% overlap), indicating direct search competition.
You've seen the gap. Now steal the playbook.
A Growth Teardown reverse-engineers exactly how each product grows — traffic sources, backlink strategy, keyword gaps, and scored action items you can copy this week.
Related Comparisons
Report based on data from July 2026